Irstran Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Side Effects Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Irbesartan

Indications/Uses

Essential HTN. Diabetic nephropathy in patients w/ type 2 diabetes & HTN.

Click to view Irstran detailed prescribing information

Dosage/Direction for Use

Usual recommended initial & maintenance dose: 150 mg once daily, may be increased to 300 mg or other antihypertensive agents may be added. Hypertensive type 2 diabetic patient Initially 150 mg once daily, may be titrated up to 300 mg once daily.

Click to view Irstran detailed prescribing information

Overdosage

View Irstran overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity. Concomitant use w/ aliskiren-containing drugs in patients w/ DM or renal impairment. 2nd & 3rd trimesters of pregnancy.

Click to view Irstran detailed prescribing information

Special Precautions

Not recommended in primary aldosteronism & dual blockade of renin-angiotensin-aldosterone system. Bilateral renal artery stenosis or artery stenosis to single functioning kidney; aortic or mitral stenosis or obstructive hypertrophic cardiomyopathy; hyperkalaemia; ischaemic cardiopathy or CV disease; hypertensive patients w/ type 2 DM or renal disease. Correct vol &/or Na depletion prior to administration. Periodic monitoring of K & creatinine serum levels. Not recommended in combination w/ lithium. Black patients. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Not recommended during 1st trimester of pregnancy & lactation. Not recommended in childn & adolescents.

Click to view Irstran detailed prescribing information

Use In Pregnancy & Lactation

Click to view Irstran detailed prescribing information

Adverse Reactions

Dizziness, orthostatic dizziness; orthostatic hypotension; nausea/vomiting; musculoskeletal pain; fatigue.

Drug Interactions

Increased hypotensive effects w/ diuretics & other antihypertensives. Higher frequency of adverse events eg, hypotension, hyperkalaemia & decreased renal function w/ aliskiren-containing drugs & ACE inhibitors. Increased serum K w/ K-sparing diuretics, K supplements, K-containing salt substitutes. Reversible increased serum lithium conc & toxicity. Attenuated antihypertensive effect w/ NSAIDs, selective COX-2 inhibitors, ASA & non-selective NSAIDs.

Click to view Irstran detailed prescribing information

Storage

View Irstran storage conditions for details to ensure optimal shelf-life.

Description

View Irstran description for details of the chemical structure and excipients (inactive components).

Action

View Irstran mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Angiotensin II Antagonists

ATC Classification

C09CA04 - irbesartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Regulatory Classification

Presentation/Packing

Form

Irstran FC tab 150 mg

Packing/Price

30's

Form

Irstran FC tab 300 mg

Packing/Price

30's

Irstran

irbesartan

Manufacturer:

Y.S.P. Industries

Distributor:

Y.S.P. Industries